Praxis Precision Medicines (PRAX) Equity Average (2022 - 2025)
Historic Equity Average for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $373.9 million.
- Praxis Precision Medicines' Equity Average fell 673.97% to $373.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $373.9 million, marking a year-over-year decrease of 673.97%. This contributed to the annual value of $257.6 million for FY2024, which is 25336.58% up from last year.
- Per Praxis Precision Medicines' latest filing, its Equity Average stood at $373.9 million for Q3 2025, which was down 673.97% from $421.7 million recorded in Q2 2025.
- Praxis Precision Medicines' Equity Average's 5-year high stood at $442.3 million during Q1 2025, with a 5-year trough of $70.3 million in Q1 2023.
- Its 4-year average for Equity Average is $231.0 million, with a median of $157.3 million in 2022.
- As far as peak fluctuations go, Praxis Precision Medicines' Equity Average plummeted by 4843.96% in 2023, and later skyrocketed by 42940.13% in 2024.
- Praxis Precision Medicines' Equity Average (Quarter) stood at $90.6 million in 2022, then dropped by 13.71% to $78.2 million in 2023, then surged by 429.4% to $414.1 million in 2024, then dropped by 9.71% to $373.9 million in 2025.
- Its last three reported values are $373.9 million in Q3 2025, $421.7 million for Q2 2025, and $442.3 million during Q1 2025.